This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
T Cell Dysfunction, Cancer and Infection
Organizer(s): Daniel C. Douek, W. Nicholas Haining and Jedd D. Wolchok
Date: January 16 - 20, 2018
Location: Beaver Run Resort, Breckenridge, CO, USA
Sponsored by Amgen Inc., Incyte Corporation, Juno Therapeutics, Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., Surface Oncology and TESARO, Inc.
Summary of Meeting:
T cell exhaustion is an acquired state of T cell dysfunction, associated with reduced T cell function, sustained expression of inhibitory receptors and a transcriptional state that is distinct from memory and effector T cells. T cell exhaustion is now recognized as a defining feature not only of chronic infections such as HIV, malaria and tuberculosis, but also of cancer. As a result, the search for effective approaches to reverse T cell exhaustion is the focus of immense therapeutic development. However, the similarities and differences between T cell dysfunction arising in chronic infection and tumors are not fully understood. Moreover, opportunities to identify new therapeutic approaches to reverse dysfunction based on parallels between the two disease states remain to be explored. This meeting will focus on the comparative biology and clinical therapeutics of T cell dysfunction in chronic viral infection and cancer. Drawing on leaders in fundamental T cell biology, computational science and clinical investigation, it will focus on common features and distinctive aspects of T cell dysfunction in cancer and chronic infection. The meeting will have broad relevance for T cell biology, tumor immunity, infectious disease and therapeutic development.
Scholarship Deadline: September 21 2017
Discounted Abstract Deadline: September 21 2017
Abstract Deadline: October 19 2017
Discounted Registration Deadline: November 20 2017
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

Amgen Inc.
Incyte CorporationJuno TherapeuticsMerck & Co., Inc.Regeneron Pharmaceuticals, Inc.Surface OncologyTESARO, Inc.
We gratefully acknowledge additional support for this conference from:
Oncotarget
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Genentech, Inc.
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1 R13 CA224785-01
Funding for this conference was made possible (in part) by 1 R13 CA224785-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found